Busting the Billion-Dollar Myth: How to Slash the Cost of Drug Development

Nature. 2016 Aug 25;536(7617):388-90. doi: 10.1038/536388a.

Publication types

  • News

MeSH terms

  • Africa
  • Amodiaquine / administration & dosage
  • Amodiaquine / therapeutic use
  • Anti-Bacterial Agents / administration & dosage
  • Anti-Bacterial Agents / economics
  • Anti-Bacterial Agents / therapeutic use
  • Artemisinins / administration & dosage
  • Artemisinins / therapeutic use
  • Benzamides / economics
  • Benzamides / therapeutic use
  • Boron Compounds / economics
  • Boron Compounds / therapeutic use
  • Child
  • Clinical Trials as Topic / economics
  • Clinical Trials as Topic / methods
  • Cooperative Behavior
  • Developed Countries / economics
  • Developing Countries / economics
  • Drug Approval
  • Drug Combinations
  • Drug Costs
  • Drug Discovery / economics*
  • Drug Discovery / methods*
  • Drug Discovery / organization & administration
  • Drug Industry / economics*
  • Drug Industry / methods*
  • Drug Industry / organization & administration
  • Drug Repositioning / economics
  • Drug Resistance, Microbial / drug effects
  • Female
  • Humans
  • Malaria / drug therapy
  • Neglected Diseases / drug therapy
  • Negotiating
  • Nitroimidazoles / economics
  • Nitroimidazoles / pharmacology
  • Nitroimidazoles / therapeutic use
  • Organizations, Nonprofit / economics*
  • Organizations, Nonprofit / organization & administration*
  • Sample Size
  • Trypanosomiasis, African / drug therapy
  • World Health Organization

Substances

  • Anti-Bacterial Agents
  • Artemisinins
  • Benzamides
  • Boron Compounds
  • Drug Combinations
  • Nitroimidazoles
  • SCYX 7158
  • Amodiaquine
  • fexinidazole
  • artemisinine